Although azacitidine is the first-line drug for higher-risk myelodysplastic syndrome (MDS) patients, its efficacy for lower-risk MDS remains unestablished. Therefore, we conducted a prospective study to examine the efficacy and safety of a 5-day regimen of azacitidine (AZA-5) for lower-risk MDS. The primary endpoint was hema- 
Although azacitidine is the first-line drug for higher-risk myelodysplastic syndrome (MDS) patients, its efficacy for lower-risk MDS remains unestablished. Therefore, and 45 patients (88.2%) received more than 4 courses. HI and transfusion independency were seen in 24 patients (47.1%) and 11 patients (39.2%), respectively. A total of 11 patients (21.6%) achieved complete remission or marrow remission. WT1 mRNA levels were not significantly correlated with therapy response. Grade 3 or 4 neutropenia and thrombocytopenia occurred in 26 (51.0%) and 11 (21.5%) patients, respectively. Nonhematological grade 3 or 4 adverse events were observed in 9 patients (17.6%). Together, these results indicate that AZA-5 is feasible and effective for lower-risk MDS patients as well as for higher-risk MDS patients.
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| INTRODUCTION
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by cytopenia in peripheral blood and subsequent leukemic transformation in a substantial proportion of the patients. 1 A hypomethylating agent (HMA), azacitidine, was reported to improve overall survival (OS) for higher-risk MDS (including acute myeloid leukemia by WHO classification) with a 7-day administration schedule (AZA-7) compared with conventional therapies. 2 In addition, a phase 1/2 AZA-7 study in Japan demonstrated that AZA was effective, safe and well tolerated in MDS patients. Based on these results, AZA was approved for MDS including all-risk groups in Japan in showed almost equivalent efficiencies and toxicities with AZA-7. 4 In addition, a phase 2 prospective study demonstrated the efficacy and safety of AZA-5 in erythropoietin-unresponsive lower-risk MDS patients. 5, 6 However, the efficacy of AZA for lower-risk MDS has not been fully clarified. Therefore, in the present study, we analyzed the efficacy and safety of AZA-5 for untreated Japanese MDS patients with lower-risk MDS, including refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS) based on the French-American-British (FAB) classification in the multicenter prospective single-arm phase 2 trial.
| PATIENTS AND METHODS

| Patient eligibility
Untreated MDS patients with lower-risk MDS (refractory anemia 
| Evaluation of response
The mRNA in peripheral blood (PB) was measured at baseline and after every AZA-5 treatment until 4 cycles at SRL (Tokyo, Japan) using a WT1 mRNA Assay Kit (Otsuka Pharmaceutical, Tokyo, Japan). In this assay, the normal range of WT1 mRNA is <50 copies per 1 μg of RNA.
| Evaluation of safety
All adverse events (AE) were monitored in patients, who received AZA at least once, from the first administration to day 29 of the last cycle and evaluated by CTCAE Version 4.0. If the patients dropped off the study before completion of the study protocol, AE were monitored until the next treatment was initiated.
| Statistical analysis
The primary endpoint of this study was the rate of HI as described above. The expected and threshold rates of HI were estimated to be 40% and 20%, respectively, based on the previous reports using the similar response criteria. 3 
| Treatment outcomes
Among 51 patients enrolled in this study, 45 patients (88.2%) received AZA-5 for more than 4 cycles. The reasons for treatment discontinuation before the 4 cycles were disease progression (n = 2) and adverse events (n = 4). A number of patients required decreasing and delayed azacitidine administration: 6/51 (11.8%) or 26/51 (51.0%), respectively.
As shown in We also compared WT1 mRNA levels before and after AZA-5 therapy between responders and nonresponders. Among 22 responders, WT1 mRNA levels increased in 6 patients (22%) regardless of their responses (Figure 1 ). There was no significant difference in the change of WT1 mRNA levels between responders and nonresponders (P = .0819) (Figure 1 ). These results indicate that WT1 mRNA levels are neither useful to predict nor to evaluate the responses to Aza-5 in MDS patients with RA or RARS.
| Hematological and nonhematological toxicity
The most common toxicity was hematologic toxicity. As shown in Table 4 , neutropenia of grade 3 was observed in 9 patients None of the patients dropped out the study due to hematologic toxicities. Nine patients developed grade 3 nonhematological toxicities: febrile neutropenia (FN) in 3 and pneumonia, diverticulitis, renal insufficiency, cerebral infarction, Sweet's syndrome and heart failure in 1 patient. Although FN, pneumonia and diverticulitis were considered to be related with AZA-5, renal insufficiency, cerebral infarction, Sweet's syndrome and heart failure were judged to be unrelated with AZA-5. As a result, 4 patients discontinued AZA-5 treatment before 4 cycles were completed due to nonhematological toxicities.
| Discussion
In this prospective trial, we evaluated the safety and efficacy of AZA-5 for untreated MDS patients with lower-risk MDS (RA and RARS based on the FAB classification). A total of 45/51 (88.2%) patients had 4 courses of therapy. The most common toxicities were hematological toxicities. However, they were all manageable and no patients dropped out of the study due to hematological toxicities.
Hypomethylating agents, including AZA, improve survival in patients with higher-risk MDS 2 but are less well-studied in lower-risk patients. In 2011 when this trial started, darbepoetin (DPO), which may be effective for anemic lower-risk MDS patients, 14 was not approved in Japan. Therefore, there were no patients treated with DPO at entry in our trial.
The HI and HR rates in the present study were 47.1% and 21.6%, respectively, which are similar to results of the previous phase I/II study of AZA in Japan 3 (AZA-7 in Japan) conducted for all-risk MDS patients. In the AZA-7 study in Japan, the HI rates in lower-risk MDS patients were 57.9% (11/19) In addition to our study, a prospective phase 2 study using AZA-5 for erythropoietin-unresponsive patients with lower-risk MDS has already been reported. 5 The overall response rate was 15/32 (47%), which was similar to the HI rate observed in our study. This study reported that some patients completing 8 cycles obtained better response than those with 4 cycles. In contrast, we planned the 4 cycle AZA-5 study in the present study according to the phase 1/2 AZA-7 study in Japan. 3 Further study to determine the appropriate treatment duration for lower-risk MDS is also necessary.
It has been reported that WT1 mRNA expression can be a useful marker for diagnosis and risk evaluation of MDS. 17, 18 Therefore, we measured WT1 mRNA expression levels to evaluate disease progression during AZA treatment. However, because there was no correlation between WT1 mRNA expression levels before treatment and therapy responses in the present study, WT1 may not be useful as a prediction marker for AZA response.
Recently, in a multicenter retrospective cohort of patients with non-del(5q) lower-risk MDS treated with erythropoietin-stimulating agents (ESA), none of the commonly used second-line treatments (HMA and lenalidomide) significantly improved OS. Early failure of ESA was associated with a higher risk of AML progression. 19 These results indicate the benefit of early treatment with AZA for lowerrisk MDS.
In conclusion, AZA-5 was effective in a substantial proportion of lower-risk MDS patients. In addition, toxicities of AZA-5 were well tolerated and clinically manageable. These results indicate that AZA-5 is a promising therapeutic option for lower-risk MDS.
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